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Original Article
The role of radiofrequency ablation to liver transection surface in 
patients with close tumor margin of HCC during hepatectomy—a 
case matched study
C. Nicholas Kotewall1, Tan To Cheung1, Wong Hoi She1, Ka Wing Ma1, Simon Hing Ying Tsang1, Jeff 
Wing Chiu Dai1, Albert Chi Yan Chan2, Kenneth Siu Ho Chok2, Chung Mau Lo3
1Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong, China; 2Department of Surgery, The 
University of Hong Kong, Hong Kong, SAR, China; 3Departments of Pathology and Surgery, State Key Laboratory for Liver Research, University 
of Hong Kong, Hong Kong 999077, China
Contributions: (I) Conception and design: TT Cheung; (II) Administrative support: TT Cheung; (III) Provision of study materials or patients: WH 
She, KW Ma, SH Tsang, JW Dai, AC Chan, KS Chok, CM Lo; (IV) Collection and assembly of data: TT Cheung, WH She, KW Ma, SH Tsang, 
JW Dai, AC Chan, KS Chok, CM Lo; (V) Data analysis and interpretation: CN Kotewall, TT Cheung; (VI) Manuscript writing: All authors; (VII) 
Final approval of manuscript: All authors.
Correspondence to: Tan To Cheung, Chief, Hepatobiliary and pancreatic Surgery Queen Mary Hospital, Clinical Associate Professor. Department of 
Surgery, The University of Hong Kong, No. 102 Pok Fu Lam Road, Hong Kong SAR, China. Email: tantocheung@hotmail.com.
Background: To review the outcome of using radiofrequency ablation (RFA) for patients with close 
resection margin during hepatectomy.
Methods: From Oct 2004 to Sept 2013, 862 patients received hepatectomy for hepatocellular carcinoma 
(HCC) in the Department of Surgery, Queen Mary Hospital in Hong Kong. Fourteen patients received 
additional RFA because of close resection margin (<1 cm) during the operation for HCC. The result of 28 
patients with close liver resection margin was selected for comparison. The two groups of patients were 
matched in terms of tumor size, tumor number, stage of disease and magnitude of resection.
Results: In the RFA group (n=14), the median age of the patients was 58.5 (range, 25–78 years). The 
median tumor size was 2.25 cm (range, 1.2–12 cm). In the resection alone group (n=28), the median age 
for the patients was 61 (range, 36–79 years). The median tumor size was 2.7 cm (range, 1–11 cm). There 
was no difference in terms of liver function assessment between the two groups. There was no RFA related 
complication recorded during the study period. There was no hospital mortality in both groups. The 1- 
and 3-year disease free survival was 38.3% and 25.5% respectively in the RFA group vs. 57.4% and 39.3% 
respectively in the liver resection alone group (P=0.563). The 1- and 3-year overall survival was 81.5% 
and 69.8% respectively in the RFA group vs .88.4% and 59.9% respectively in the liver resection alone  
group (P=0.83). 
Conclusions: RFA to hepatectomy resection surface in patients with close margin is a safe treatment 
option but its effectiveness on prevention of local recurrence has yet to be confirmed.
Keywords: Close resection margin; hepatocellular carcinoma (HCC); radiofrequency ablation (RFA); case-
matched study
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer with around 750,000 new patients 
every year (1,2). Surgical resection is regarded as the 
standard treatment with curative intent for HCC as 
suggested by Asia Pacific Association for the Study of Liver 
Disease guideline (3). The operative mortality is less 
than 5% for major hepatectomy and the 5-year survival 
is 50% (4). However, not all patients are suitable for 
surgical resection (5). The presence of multifocal disease, 
proximity of tumor to major vascular and biliary structures 
preventing adequate resection margin, advance tumor 
staging on presentation or insufficient liver remnant volume 
are all contra-indications for major resection (6). Liver 
transplantation provides an alternative curative treatment 
for a selected group of HCC patients, but the paucity of 
liver grafts limits the application of the approach (7,8). 
The long-term survival of HCC is unsatisfactory because 
of high recurrence rate which at 5 year is 75% (9). The 
recurrence can be divided into local recurrence and 
intrahepatic metastasis (10). The pathogenesis of local 
recurrence is thought to be related to the presence 
of residual tumor cell,  leading to regrowth of the 
tumor and the risk factors include large tumor size, 
multiple tumor nodules, and vascular invasion (11). On 
the other hand, intrahepatic metastasis is due to the 
spread of micrometastasis by means of portal venous 
dissemination (12). Studies have shown that deposition 
of microsatellites occur anywhere from 0.5 to 6 cm away 
from the main tumor (13). The surgical resection margin 
has no effect on the tendency of the tumor to develop 
microsatellites (14). Tumor biology, namely Edmundson 
score of differentiation, size and presence of capsule are 
predictors of the pattern of microsatellite deposition (15).
As local recurrence is thought to be related to the 
presence of residual tumor cells, resection margin is a 
surgical factor which has been evaluated for its influence 
on the long term outcome after resection, but its precise 
significance remains to be determined (16). Whenever 
possible, anatomical resection based on segmental liver 
anatomy is the preferred technique of choice because it may 
prevent intrahepatic recurrence by eradicating intrahepatic 
microscopic tumor foci. Makuuchi’s group was the first to 
describe anatomical resection which entails removing the 
entire liver segment, where the tumor resides, together 
with its vascular and biliary tributaries so that microsatellite 
tumor foci could be removed concurrently (17). However, 
anatomical resection is not always possible. Proponents of 
nonanatomical resection have stressed the importance of 
preserving the functional liver reserve and preventing liver 
failure. For most patients undergoing resection for HCC, a 
majority of them suffers from Hepatitis B virus or C virus 
related liver cirrhosis. In their case, an aggressive approach 
is needed to preserve the noncancerous liver parenchyma, 
otherwise liver failure might ensue. Cirrhotic livers lack 
the regenerative potential of healthy liver parenchyma. 
Therefore, although anatomical resection offers the best 
oncological control, it is not always the best operative 
option. For subcapsular wedge resection of HCC less than 
3 cm and in patients where anatomical resection is not 
possible, a 1 cm margin is recommended (13).
Besides the issue of the healthy liver preservation, there 
are also anatomical and technical concerns with securing 
adequate margin. Tumor location occasionally precludes 
the achievement of adequate margin. Close proximity to 
major vascular and biliary structures, and deep location of 
tumor are such examples. Additionally, there are technical 
concerns. In cirrhotic livers, intra-operative ultrasound can 
sometimes fail to provide accurate information (18). The 
surgeon can misjudge the exact extent and location of the 
tumor. This is usually discovered during the examination 
of the specimen after the resection is completed. In such 
scenarios, a re-resection to establish adequate margin will 
prolong operation time, and incurred additional blood loss 
which can be detrimental to the patient. This study aims 
to investigate the role of radiofrequency ablation (RFA) to 
HCC resection bed when the margin is intra-operatively 
found to be suboptimal.
RFA is an ablative surgical technique which produces 
coagulative necrosis created by alternating high frequency 
electric current (19,20). Heat is created by the movement 
of the ions within the tissues as they are agitated by the 
current. At high temperature, proteins are denatured and 
microvasculature is destroyed by thrombosis (21). Proximity 
to large blood vessel plays a role in the heat transmission. 
Blood flow protects the vessel wall from damage but also 
act a heat sink and cools nearby tissue, limiting the effect 
of RFA (22). A major safety concern for the use of RFA in 
HCC is the potential damage to nearby bile ducts caused 
by the heat generated by this device. The damage results in 
causes stenosis and distal obstruction. A method to counter 
potential biliary injury is intraductal cooling of the central 
bile duct (23).
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Methods
Between October of 2004 and September 2013, 862 patients 
underwent hepatectomy for HCC with macroscopically 
complete resection of tumor in the Department of Surgery 
at the University of Hong Kong at Queen Mary Hospital. 
Fourteen patients received additional RFA because of close/
involved resection margin found intraoperatively. Another 
28 patients with similarly close resection margin but did 
not received additional RFA was selectively matched for 
comparisons. These two groups of patients were matched 
according to the tumor size, the number of tumors, 
pathological stage of their disease and the magnitude of the 
resection. 
All patients were regularly followed up at our outpatient 
clinic and were monitored for recurrence by serum alpha-
fetoprotein level assessment and contrast CT scan every 
4–6 months. A computerized database has been established 
for collection of clinical and pathological data of all patients, 
including size of tumor, resection margin as assessed by 
pathologists. Any post-operative recurrence was entered 
into the database after confirmation of diagnosis. 
Surgical margin was defined as the shortest macroscopic 
distance from the edge of the tumor to the line of 
transection with close being less than 1 cm. Both groups 
were matched according tumor, patient and biochemical 
parameter. For tumor factors, size, number, Edmundson 
grade of differentiation pathological TMN staging and 
resection margins were matched. For patient factors, 
age, gender, hepatitis B/C virus status, the medical 
comorbidities, Child-Pugh grade of liver cirrhosis 
and indocyanine green retention test were matched. 
Biochemically, the pre-operative liver and renal function, 
the alpha-fetal protein were matched. The peri-operative 
data including blood loss, duration of operation, the type 
of resection and length of hospital admission were all taken 
into account.
Statistical analysis
The computer software SPSS, version 21.0, from IBM 
SPSS Statistics was used for statistical analyses. 
Comparisons between the two groups were performed 
using the Pearson chi-square test for nominal variables 
and the Mann Whitney U test was used for continuous 
variables. Cumulative survival and recurrence rates were 
evaluated by the Kaplan-Meier method and compared by 
the log-rank test. All statistical analyses were performed 
using statistical software (SPSS version 21.0. from IBM 
SPSS statistics, Chicago, IL, USA). P value of less than 0.05 
was considered statistically significant. 
Results
Among the 862 patients, 14 with close resection margin, 
which was defined as less than 1 cm, received additional 
RFA to the surgical margin intra-operatively. These 14 
patients were compared with another 28 patients with 
close margin who did not receive RFA. Both groups are 
extensively matched. 
The detailed of the close proximity to margin is listed 
in Table 1. Historic controls of similar situations without 
RFA were selected for comparison in a ratio of 1:2. They 
matched in tumour number, tumour size and stage of 
disease.
The patients’ demographic conditions are listed in 
Table 2 in detail. 
There was no difference between the two groups.
The complication profiles between the two groups 
are similar. Five patients (18%) had complications in the 
control group and two patients (14%) had complication in 
the RFA group (P=1).
Long-term outcomes in terms of overall survival and 
post-operative recurrence rates were similar between the 
two groups. The 1-, 3-, 5-year overall survival rates were 
respectively 82%, 70% and 70% in the RFA group and 
for the controlled groups these numbers are 88%, 60% 
and 46% (P=0.83). Analyses after stratification of patient 
according to tumor size revealed no significant difference 
between the two groups. 
During the follow-up period, recurrence developed 57% 
in the control group and 50% in the RFA group (P=0.41). 
There are no significant differences between the two groups 
in terms of type of recurrence.
The 1-, 3-year disease free survival rate were respectively 
38% and 26% for the RFA group. In comparison the 
numbers are 57% and 39% for the control group. Analyses 
after stratification of patients according to tumor size 
revealed no significant difference between the two groups.
Table 3 shows the operative and pathological details of 
the two groups.
Subgroup analyses of tumour cut off value of 3 cm were 
compared for overall survival rates (Figures 1,2). Subgroup 
analyses of tumour cut off value of 3 cm were compared for 
disease free survival rates (Figures 3,4). 
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2017;2:33tgh.amegroups.com
Page 4 of 9 Translational Gastroenterology and Hepatology, 2017
Discussion
Resection is the gold standard of treatment for HCC for 
patients who are fit to undergo operation. Anatomical 
resection offers the best chance of cure. The removal of 
associated segmental vascular and biliary tributaries reduces 
the likelihood of microsatellite tumor deposit and neoplastic 
emboli in the small portal branches which are connected to 
the neovascularization of the tumor. However this approach 
is not always possible. The advent of RFA has provided an 
alternative option for treating HCC. For small tumors less 
than 2 cm, the survival benefit using RFA has proven to be 
on par with resection. However, similar data does not exist 
for larger tumors, in which case, resection remains the only 
hope of cure. 
In patients with cirrhotic liver from chronic hepatitis 
virus infection, preservation of functional residual 
parenchyma is paramount to avoid post-operative liver 
failure. In such case where anatomical resection is not 
feasible, an adequate resection margin of 1 cm is usually 
recommended. 
Some studies have shown that the amount of resection 
margin around small HCC does not influence postoperative 
recurrence rates. In other words, margin less than 1 cm 
are occasionally acceptable. Small tumors measuring 
1.5 cm or less are usually well differentiated. Well 
differentiated tumors give rise to less portal microinvasion 
and microsatellite formation. The degree of tumor 
differentiation is related to the size of the tumor. Larger 
tumors are less well differentiated which will result in more 
portal microinvasion and tumor microsatellites, normally 
within 1 cm of the main tumor. 
Achieving a 1 cm resection margin is, however, often 
not feasible for large HCCs. Tumor location and other 
technical factors sometimes preclude surgeons from 
achieving the desired resection margin. For tumors abutting 
major vessels, a less than optimal margin is usually accepted 
in order to preserve the vasculature which is needed to 
provide adequate supply and drainage to the liver remnant. 
Table 1 The clinicopathologic data of these two groups of patients 
Tumor characteristics Control (n=28, %) RFA ablation on margin (n=14, %) P value
Resection margin (cm) [median (range)] 0.977
Involved (i.e., 0 cm) 7 (25.0) 4 (28.6)
0.05 cm 1 (3.6) 0 (0)
0.1 cm 4 (14.3) 2 (14.3)
0.2 cm 6 (21.4) 4 (28.6)
0.3 cm 2 (7.1) 0 (0)
0.4 cm 3 (10.7) 1 (7.1)
0.5 cm 1 (3.6) 1 (7.1)
0.8 cm 2 (7.1) 1 (7.1)
1.0 cm 2 (7.1) 1 (7.1)
TNM staging [1997] 5th edition 0.357
I 4 (14.3) 4 (28.6)
II 10 (35.7) 3 (21.4)
IIIA 10 (35.7) 3 (21.4)
IVA 4 (14.3) 4 (28.6)
Tumor size [median (range)] 1
≤3 cm 20 (71.4) 10 (71.4)
>3 cm 8 (28.6) 4 (28.6)
There were no significant differences in any of the tumor factors, including resection margin, TMN stage, and size.
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Table 2 The data comparing these two groups regarding patient factors including age, gender, hepatitis status, comorbidities, presence of ascites, 
Child-Pugh grade, ICG retention at 15 min, biochemistry, and tumor number
Patients’ characteristics Control (n=28) RFA ablation on margin (n=14) P value
Age [median (range)] 61 (36.0–79.0) 58.5 (25.0–78.0) 0.362
Sex (male:female) 24:4 12:2 1.000
Hepatitis B (positive) 23 (82.1%) 13 (92.9%) 0.640
Hepatitis C (positive) 1 (3.6%) 0 (0%) 1.000
Comorbid disease (yes, %) 16 (57.1%) 3 (21.4%) 0.028
Heart 12 (42.9%) 3 (21.4%) 0.172
Lung 7 (25.0%) 1 (7.1%) 0.331
Renal 2 (7.1%) 1 (7.1%) 1.000
DM 5 (17.9%) 0 (0%) 0.238
Gastrointestinal 3 (10.7%) 3 (21.4%) 0.640
Ascite –
Absent 28 (100.0%) 14 (100.0%)
Child-Pugh grade 1.000
A 27 (96.4%) 13 (92.9%)
B 1 (3.6%) 1 (7.1%)
C – –
ICG 15 min (%) 12.75 (5.9–36.8) 14 (7.0–62.2) 0.396
Pre-operative chemistry data
Serum bilirubin 10 (4.0–22.0) 10 (3.0–21.0) 0.843
Creatinine 85.5 (52.0–117.0) 90 (63.0–131.0) 0.436
Albumin 40 (29.0–49.0) 41.5 (27.0–48.0) 0.189
INR 1 (0.9–1.3) 1.1 (0.9–1.3) 0.420
Platelet count 157 (46.0–258.0) 140.5 (82.0–278.0) 0.501
AFP 10.5 (2.0–478.0) 115 (4.0–16,744.0) 0.004
AST 37 (18.0–85.0) 45 (21.0–108.0) 0.272
ALT 37 (18.0–96.0) 30.5 (15.0–117.0) 0.390
HGB 14.15 (11–16.9) 13.3 (11.2–15.4) 0.198
Size of tumor (cm) [median (range)] 2.7 (1.0–11.0) 2.25 (1.2–12.0) 0.589
No. of tumor(s) 0.739
1 22 (78.6%) 9 (64.3%)
2 3 (10.7%) 3 (21.4%)
3 1 (3.6%) 1 (7.1%)
Multiple 2 (7.1%) 1 (7.1%)
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Table 3 Intra-operative and post-operative data of these two groups of patients
Intraoperative/postoperative data Control (n=28) RFA ablation on margin (n=14) P value
Blood loss (L) 0.4 (0.02–3.30) 0.51 (0.02–1.80) 0.390
Blood transfusion (L) 0 (0–2.56) 0 (0–0.64) 0.906
Blood transfusion (yes, %) 3 (10.7%) 2 (14.3%) 1.000
Hospital stay (days) 7 [3–41] 8 [3–21] 0.722
Hospital mortality 0 (0%) 0 (0%) –
OT duration (min) 291.5 [129–883] 239.5 [120–485] 0.362
Type of operation 0.853
Major 2 (7.1%) 2 (14.3%)
Minor 26 (92.9%) 12 (85.7%)
Pattern of recurrence 0.406
Nil 12 (42.9%) 7 (50.0%)
Intrahepatic 12 (42.9%) 3 (21.4%)
Extrahepatic 1 (3.6%) 2 (14.3%)
Both recurrence 3 (10.7%) 2 (14.3%)
New Edmonson grade 0.783
Well-differentiated 5 (17.9%) 4 (28.6%)
Moderately-differentiated 18 (64.3%) 8 (57.1%)
Poorly differentiated 4 (14.3%) 2 (14.3%)
Not available 1 (3.6%) –
There are no significant differences between the Edmonson grade, blood loss, operation time, type of resection, duration hospital stay and 
type of recurrence.
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Figure 1 Overall survival of tumors up to 3 cm. Figure 2 Overall survival for tumors larger than 3 cm.
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Technical errors of judgement might also results in 
inadequate resection margin. Surgical planning error can 
occur because intra-operative ultrasound localization of 
tumor can be difficult to interpret in the background of 
liver cirrhosis. It is only after the delivery of the specimen 
and during on-table examination that an inadequate 
margin is discovered. In such cases, re-resection is 
possible but would results in more blood loss and longer 
operation duration which many older patients cannot 
tolerate.
In such scenarios, RFA has been adopted to create a 
surrogate margin. RFA is an ablative technology which 
employs alternating high frequency electric current to 
produce coagulative necrosis (24). The RFA is applied 
to the surgical resection bed after the discovery of 
inadequate margin. The probe which transmits the 
energy creates zone of necrosis. This area serves as a 
buffering resection margin. Using ablation technology 
is faster than re-resection. Another advantage is the 
fact that the treatment modality is also associated with 
minimal blood loss. 
This study examines the benefits and risks of using RFA 
in cases where the resection margin has been found intra-
operatively to be less than satisfactory. The postulation 
is that RFA will confer additional survival benefit, 
especially regarding reduction in marginal recurrence. 
However, the data has failed to produce any concrete 
evidence to support the hypothesis. The pathophysiology 
of HCC recurrence is twofold. The cirrhotic liver is 
premalignant, and this explains the multicentric nature 
of HCC recurrence. The second type of recurrence is 
marginal recurrence in which the tumor arises quickly 
after the operation at the edge of the resected area. The 
postulation behind this type of pattern is the presence 
of tumor microsatellites which are usually present 
within 1cm from the main tumor bulk. In these cases, an 
inadequate margin during operation would likely result 
in rapid recurrence. In order to reduce rapid recurrence 
near the surgical bed after operation, an adequate margin 
should be achieved. However, as explained earlier, that is 
not always feasible. The application of RFA to the surgical 
bed can theoretically create a surrogate margin with the 
1 cm zone of necrosis it induces. Despite the logical basis 
of this assumption, we have failed to prove any survival 
benefit with this technique in the study. 
Nonetheless, the examination of the data proves that 
the technique is safe and the complication profile is the 
same as the control group. 
The main limitation of this study is the small sample 
size. Although the scale of the study is small, it is one of 
the first to examine the use of RFA in tumor with close 
resection margin. The information we have gain from this 
study fills a void in the literature. The benefits have not 
been demonstrated thus far but as numbers accrue, the 
results might be different. This study is also retrospective 
in nature which limits the power of its conclusion. 
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Figure 3 Disease free survival for tumors up to 3 cm. Figure 4 Disease free survival for tumor larger than 3 cm.
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However, a randomized controlled trial would be difficult 
to conduct for this scenario. 
Close resection margin in surgery for liver tumor is 
often encountered. Perhaps, it might be unavoidable. 
Finding a solution to remedy this problem will be pivotal 
to reduce local recurrence rates. In this study, the use 
of RFA has failed to show any concrete benefit but it is 
proven to be safe. Conceptually, the RFA zone should act 
as a surrogate resection margin if properly executed; more 
research is needed to confirm the conclusion of this study 
and to explain the findings.
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